Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 145

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 145
---
 believe there are adequate options and time available to secure additional financing for the Company and after considering
the uncertainties, we consider it is appropriate to continue to adopt the going concern basis in preparing the financial information.
Our consolidated financial information have therefore been presented on a going concern basis, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business.

We
have prepared cash flow forecasts and considered the cash flow requirement for our next three years, including the period twelve months
from the date of the approval of the financial statements. These forecasts show that further financing will be required during the course
of the next 12 months, assuming, inter alia, that certain development programs and other operating activities continue as currently planned. If
we do not secure additional funding before the end of the first quarter of 2025, we will no longer be a going concern and would likely
be placed in administration.

In
our opinion, the environment for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition
and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings by us
are likely to be dilutive. We continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially
available to the Company. Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be
no assurance that any alternative courses of action to finance the Company would be successful.

This
requirement for additional financing represents a material uncertainty that raises substantial doubt about our ability to continue as
a going concern. As a result, our independent registered public accounting firm included an explanatory paragraph in its report on our
financial statements as of and for the year ended December 31, 2023 with respect to this uncertainty. Should it become evident in the
future that there are no realistic financing options available to us which are actionable before our cash resources run out then we will
no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under paragraph 25 of
IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would stated at net realizable value and
all liabilities would be accelerated to current liabilities.

Our
ability to continue as a going concern is dependent upon our ability to obtain additional capital and/or dispose of assets, for which
there can be no assurance we will be able to do on a timely basis, on favorable